![Daniel O'Hanlon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Daniel O'Hanlon
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Index Ventures SA
![]() Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland.
25
| Private Company | Investment Managers | 25 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Daniel O'Hanlon
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Medicxi Ventures (Jersey) Ltd.
![]() Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder Founder Private Equity Investor Private Equity Analyst | |
Index Venture Management (US), Inc.
![]() Index Venture Management (US), Inc. Investment ManagersFinance Founded in 2011, Index Venture Management (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Index Venture Management SA | Investment Managers | Private Equity Investor Private Equity Investor Chief Tech/Sci/R&D Officer Private Equity Investor | |
Harvard University
![]() Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Masters Business Admin | |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Mind-NRG SARL
![]() Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Medical/Nursing Services | Chairman Director/Board Member | |
Palladio Biosciences, Inc.
![]() Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Director/Board Member Director/Board Member | |
Janpix Holdings, Inc.
![]() Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Index Ventures (UK) LLP | Investment Managers | Private Equity Investor Private Equity Investor | |
TopiVert Ltd.
![]() TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Akamis Bio Ltd.
![]() Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member | |
Escuela de Organización Industrial | College/University | Masters Business Admin | |
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Touchstone Innovations Investment Management Ltd.
![]() Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member | |
University of Barcelona | College/University | Doctorate Degree | |
Minoryx Therapeutics SL
![]() Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member | |
Aravis AG
![]() Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Private Equity Investor | |
NanoDimension Management Ltd.
![]() NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | Investment Managers | Private Equity Investor | |
EVENTBRITE, INC. | Packaged Software | Founder | |
IP Group Plc /Venture Capital/
![]() IP Group Plc /Venture Capital/ Investment ManagersFinance IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Vandria SA
![]() Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member | |
CytoKi Pharma ApS
![]() CytoKi Pharma ApS Miscellaneous Commercial ServicesCommercial Services CytoKi Pharma ApS engages in the research and experimental development within biotechnology. It develops therapeutics for serious tissue and organ injuries. The company was founded by Rasmus Jørgensen on June 12, 2019 and is headquartered in Vaerlose, Denmark. | Miscellaneous Commercial Services | Director/Board Member | |
Cornell University
![]() Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Graduate Degree | |
Ecole Centrale Lyon | College/University | Graduate Degree | |
Eventbrite UK Ltd.
![]() Eventbrite UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Eventbrite, Inc., Eventbrite UK Ltd. is a company that operates a platform for live experiences. The company is based in London, UK. The platform enables users to create, share, find, and attend events. The British company was founded in 2011 by Julia D. Hartz, Renaud Visage, and Kevin Earnest Hartz. Julia D. Hartz has been the CEO since 2011. | Miscellaneous Commercial Services | Founder | |
LGT Capital Partners AG
![]() LGT Capital Partners AG Investment ManagersFinance LGT Capital Partners AG (LGT Capital Partners) is a venture capital subsidiary of LGT Holding International AG founded in 1997 by Thomas Weber. The firm is headquartered in Pfäffikon, Switzerland. | Investment Managers | Private Equity Investor | |
École Polytechnique Fédérale de Lausanne | College/University | Graduate Degree | |
Duke University
![]() Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Graduate Degree | |
TATTS GROUP LIMITED | Movies/Entertainment | Investor Relations Contact | |
JUMBO INTERACTIVE LIMITED | Casinos/Gaming | Director/Board Member | |
DMC Partners (London) Ltd.
![]() DMC Partners (London) Ltd. Investment ManagersFinance DMC Partners (London) Ltd. engages in investment activities. The firm intends to invest in China, Russia, Southeast Asia, Turkey and sub-Saharan Africa regions. The company founded by Edward Kirill Eisler, Samuel Jonathan Wisnia and Christopher Michael Barter and is headquartered in London, the United Kingdom. | Investment Managers | Chief Operating Officer | |
New York University | College/University | Masters Business Admin | |
VaxNewMo LLC
![]() VaxNewMo LLC BiotechnologyHealth Technology VaxNewMo LLC is an early-stage biotechnology company based in St. Louis, MO. The company is developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. The omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell. The company is breaking through the barrier of limited range of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation. The company was founded by Mario Feldman, Christian Harding, and Christine Szymanski. Michael Timothy Cooke has been the CEO of the company since 2022. | Biotechnology | Chairman | |
Villaris Therapeutics, Inc.
![]() Villaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Villaris Therapeutics, Inc. is an asset-centric biopharmaceutical company. The company is based in Cary, NC. The company was founded in 2019 by John Harris. The CEO is Andrea Epperly. | Pharmaceuticals: Major | Director/Board Member | |
Stx Pharma Ltd. | Director/Board Member | ||
Human Antibody Factory Ltd.
![]() Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Biotechnology | Director/Board Member | |
Kymo Therapeutics Ltd.
![]() Kymo Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kymo Therapeutics Ltd. develops and commercializes therapeutic products . The company was founded on May 23, 2016 and is headquartered in Hatfield, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Kaerus Bioscience Ltd. | Director/Board Member | ||
Mavalon Therapeutics Ltd.
![]() Mavalon Therapeutics Ltd. Medical SpecialtiesHealth Technology Mavalon Therapeutics Ltd. develops orally available small molecule able to induce glial cell line-derived neurotropic factor production within the brain of parkinson’s patients. The company is headquartered in Hatfield, the United Kingdom. | Medical Specialties | Director/Board Member | |
Diasome Pharmaceuticals, Inc.
![]() Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Pharmaceuticals: Major | Director/Board Member | |
Medicxi Ventures (Jersey) Ltd. (Switzerland) | Corporate Officer/Principal | ||
Kaerus Bioscience France SASU
![]() Kaerus Bioscience France SASU Miscellaneous Commercial ServicesCommercial Services Kaerus Bioscience France SASU engages in research and development in biotechnology. The company was founded on February 23, 2017 and is headquartered in Orléans, France. | Miscellaneous Commercial Services | Chief Executive Officer | |
Pega-One SAS | Director/Board Member | ||
Pearl River Bio GmbH | Director/Board Member |
Statistik
International
Vereinigte Staaten | 17 |
Vereinigtes Königreich | 15 |
Schweiz | 7 |
Frankreich | 5 |
Niederlande | 4 |
Sektoral
Health Technology | 16 |
Consumer Services | 12 |
Finance | 10 |
Commercial Services | 6 |
Health Services | 3 |
Operativ
Director/Board Member | 135 |
Private Equity Investor | 43 |
Corporate Officer/Principal | 24 |
Independent Dir/Board Member | 20 |
Founder | 13 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Michelangelo Volpi | 57 |
Michèle Ollier | 40 |
Giovanni Rizzo | 20 |
Tony Zappalá | 14 |
Jan Hammer | 13 |
Daniel Bach | 13 |
Jonathan Edwards | 12 |
Giovanni Mariggi | 11 |
Richard S. Rimer | 10 |
Rémy Henri Luthringer | 10 |
Salman Farmanfarmaian | 9 |
Christopher Barchak | 9 |
Roman J. Fleck | 8 |
Sachi Blue Smith | 6 |
Ari Hegalson | 6 |
- Börse
- Insiders
- Daniel O'Hanlon
- Unternehmensverbindungen